You have 0 items in your cart
Metabolic research is entering a new phase.
For several years, much of the attention has centred on developing individual compounds capable of activating multiple metabolic pathways — moving from GLP-1 agonists to dual agonists such as tirzepatide and then triple agonists such as retatrutide.
But another strategy is now attracting serious attention:
combining different metabolic compounds that act through complementary hormonal systems.
One of the newest examples is EloraTZP, an investigational combination of eloralintide and tirzepatide.
Fresh Phase 2 results presented in September 2026 have made EloraTZP one of the more interesting emerging programmes in metabolic research.
So what exactly is EloraTZP, how does it work, and how is it different from tirzepatide alone?
What is EloraTZP?
EloraTZP is an investigational metabolic treatment being developed by Eli Lilly and Company.
It combines two compounds:
Eloralintide — a selective amylin receptor agonist.
Tirzepatide — a dual GIP and GLP-1 receptor agonist.
Rather than attempting to incorporate all of these actions into one molecule, EloraTZP combines two complementary compounds to target three hormonal pathways: amylin, GIP and GLP-1.
That makes it a distinctly different approach from simply developing another GLP-1 drug.
How does EloraTZP work?
The combination brings together three metabolic signalling systems.
Tirzepatide activates receptors for GIP and GLP-1, while eloralintide preferentially targets the AMY1 amylin receptor.
Amylin is naturally released alongside insulin after eating and is involved in signalling associated with satiety and food intake.
GIP and GLP-1 are incretin hormones with important roles in metabolic and glucose regulation.
The research question behind EloraTZP is therefore straightforward:
Could targeting amylin alongside GIP and GLP-1 produce complementary effects that aren’t achieved by incretin signalling alone?
Recent clinical research suggests this is worth investigating further.
Is EloraTZP the same as tirzepatide?
No.
Tirzepatide is a single molecule that activates the GIP and GLP-1 receptors.
EloraTZP adds eloralintide and therefore introduces amylin receptor signalling as an additional pathway.
This distinction is important.
EloraTZP isn’t simply a new dose or version of tirzepatide. It represents a different strategy involving the combination of an incretin-based compound with a selective amylin receptor agonist.
What is eloralintide?
We’ve previously covered eloralintide separately at Klarity Research.
Eloralintide, also known as LY3841136, is an investigational long-acting selective amylin receptor agonist.
Unlike traditional approaches that activate multiple amylin and calcitonin receptors, it has been designed to preferentially activate AMY1R.
Lilly is already advancing eloralintide into Phase 3 studies through its ENLIGHTEN programme.
The EloraTZP programme investigates what happens when this amylin-based mechanism is combined with tirzepatide.
What did the latest EloraTZP trial find?
This is where the story has become particularly current.
On 30 September 2026, Lilly announced results from a 48-week Phase 2b study involving 367 adults with obesity or overweight and type 2 diabetes.
Participants receiving the investigated EloraTZP combinations experienced average body-weight reductions of up to 23.3%, compared with 14.8% for participants receiving tirzepatide 15 mg in the study.
Average HbA1c reductions reached up to 2.9 percentage points with the combination, compared with 2.4 percentage points for tirzepatide 15 mg.
These results shouldn’t be interpreted as establishing what will happen outside the trial or in different populations.
But scientifically, they provide evidence supporting further investigation of amylin + incretin combination therapy.
Is EloraTZP a triple agonist?
This question needs a little clarification.
Functionally, EloraTZP targets three hormone receptor systems:
amylin + GIP + GLP-1.
However, it isn’t a single triple-agonist molecule in the same way that retatrutide is.
Retatrutide is one molecule designed to activate the GIP, GLP-1 and glucagon receptors.
EloraTZP instead combines two compounds to produce activity across amylin, GIP and GLP-1 pathways.
Lilly describes EloraTZP as a triple-acting investigational medicine.
That distinction is useful when comparing the next generation of metabolic research.
EloraTZP vs retatrutide: what’s the difference?
Although both involve three hormonal pathways, their biology is quite different.
Retatrutide targets:
GIP + GLP-1 + glucagon.
EloraTZP targets:
GIP + GLP-1 + amylin.
This means researchers are effectively exploring two different ways of extending beyond conventional incretin therapy.
One incorporates glucagon receptor agonism.
The other adds amylin receptor agonism.
Determining the relative advantages and limitations of these strategies will require considerably more clinical research.
EloraTZP vs CagriSema
Another useful comparison is CagriSema.
CagriSema combines the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide.
Both programmes therefore explore the broader concept of combining GLP-1/incretin signalling with the amylin system.
But the compounds and receptor profiles aren’t identical.
EloraTZP combines a selective amylin receptor agonist with tirzepatide’s dual GIP/GLP-1 activity, meaning three metabolic pathways are involved.
This makes the comparison scientifically interesting rather than simply a question of which compound produces a larger number on a particular trial endpoint.
Is EloraTZP approved?
No.
EloraTZP remains investigational.
The September results came from a Phase 2b trial.
Based on those findings, Lilly says it plans to begin Phase 3 development of EloraTZP as a co-formulation by the end of 2026.
Phase 3 research will provide substantially more information about the combination.
Is EloraTZP available in the UK?
Not as an approved medicine.
Although tirzepatide itself is an authorised medicine, combining it experimentally with eloralintide is a different matter.
Eloralintide remains investigational, and EloraTZP has not received marketing authorisation.
That distinction is particularly important as awareness of experimental metabolic compounds increases online.
Why are researchers interested in amylin?
GLP-1 has dominated public discussion of metabolic science, but human metabolism isn’t controlled by one hormone.
Amylin represents another important component of nutrient-related signalling.
This is why several major research programmes are now investigating the pathway.
Your Klarity series has already covered petrelintide and eloralintide, while other programmes are investigating approaches combining GLP-1 and amylin signalling.
The emerging question is increasingly not:
“What comes after GLP-1?”
It may instead be:
“Which pathways work best alongside GLP-1?”
What happens next for EloraTZP?
The major development to watch is Phase 3.
Lilly has stated that it plans to advance the combination into Phase 3 as a co-formulation.
That will allow researchers to investigate the approach in much larger populations and provide considerably more evidence on efficacy, tolerability and longer-term outcomes.
It also means EloraTZP is likely to become a much more commonly searched term as the programme progresses.
The next generation may be about combinations
The metabolic research landscape is becoming increasingly diverse.
We now have research involving:
GLP-1 agonists.
GIP/GLP-1 dual agonists.
GIP/GLP-1/glucagon triple agonists.
Selective amylin receptor agonists.
GLP-1/amylin molecules.
And now combinations bringing amylin signalling together with dual incretin agonism.
EloraTZP illustrates how quickly this field is moving.
Instead of searching for one universal metabolic pathway, researchers are increasingly investigating how multiple complementary biological signals can be targeted together.
At Klarity Research, we’ll continue following these emerging pathways and the research shaping the next generation of metabolic science.
For educational and research information only. This article is not medical advice.